GlobalData Plc

The global market for spinal fusion, which includes spinal plating systems, interbody devices, vertebral body replacement devices, and pedicle screw systems (excluding minimally invasive spine devices), is set to rise from approximately $7.1 billion in 2016 to just under $9 billion by 2023, representing a compound annual growth rate of 3.4%, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report states that this relatively steady market growth, which covers 39 countries, will primarily be driven by the growing prevalence of degenerative spinal conditions due to aging, continued technological advancements in spinal fusion surgeries, such as expendable interbody cages and navigation systems, and the increased adoption of minimally invasive techniques.

Linda Tian, MSc, GlobalData’s Managing Analyst covering Medical Devices, explains: “There are several conditions in which the fusion procedure has emerged as the gold standard for surgical intervention. In the instance of symptomatic degenerative disc disease within the cervical spine, anterior cervical discectomy and fusion is widely viewed as the hallmark procedure to be performed, given its persisting performance in large-scale studies with substantial follow-up.

“Additionally, fusion surgery has been proven to provide better clinical outcomes for spondylolisthesis patients than conservative care alone or decompression surgery alone. The excellent performance of spinal fusion in these indications will continue to drive the procedure’s adoption.”

Despite the clear benefits of fusion surgery, the US healthcare system has grown wary of the extensive growth of spinal fusion procedures, as data emerge indicating the number of medically unnecessary surgeries that are being performed. Medicare estimates that more than $200 million was spent on improperly indicated spinal fusion procedures in 2011.

Tian continues: “New measures to combat the soaring number of procedures will temper the spinal fusion procedural growth rate seen in the past, as surgeons are going to be less likely to perform the procedure on patients for whom they do not have proper documentation and justification that complies with the insurer’s policies.

“In other regions, however, such measures are not in place to restrict market growth. In Europe, spine surgeons are afforded the autonomy to perform the procedure in the indications that they see fit. Additionally, they are not required to document a treatment regimen of non-conservative therapy prior to receiving the surgery in order to get reimbursed. Thus, the flexibility of surgeons to perform the procedure in a multitude of indications with minimal interference will continue to boost the European spinal fusion space.”

Information based on GlobalData’s report: MediPoint: Spinal Fusion – Global Analysis and Market Forecasts.

Related Reports

From GlobalData’s report:

MediPoint: Spinal Fusion – Global Analysis and Market Forecasts Free Sample

Related GlobalData Reports

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF